摘要
目的:观察小儿止咳颗粒对小儿咳嗽变异性哮喘的临床疗效及其对肺功能的改善情况。方法:80例咳嗽变异性哮喘患儿随机分为治疗组和对照组,每组40例。治疗组与对照组分别给予小儿止咳颗粒、孟鲁司特钠片口服治疗4周。比较两组的临床疗效以及治疗前后第1秒最大用力呼气量(FEV1)、最大呼气流速(PEF)、用力肺活量(FVC)变化。结果:经治后,两组的症状总积分均有明显改善(P<0.05),其中治疗组临床控制20例,显效17例,好转2例,总有效率97.5%;而对照组临床控制18例,显效16例,好转4例,总有效率为95.0%,两组差异无统计学意义(P>0.05)。两组治疗后FEV1、PEF、FVC均较治疗前显著改善(P<0.05),两组间的差异无统计学意义(P>0.05)。结论:小儿止咳颗粒能明显改善CVA患儿的临床症状、体征与肺功能。
Objective：To observe clinical therapeutic efficacy and the improvement of the Xiaoer Zhike granules on lung function in children with cough variant asthma. Methods：80 children who suffered from cough variant asthma were randomly divided into treatment group and control group, 40 cases for each. The Xiaoer Zhike granule was applied in treatment group and montelukast sodium tablets was adopted in control group for 4 weeks. Clinical therapeutic efficacy in two groups and the changes of FEV1, PEF and FVC were observed. Results：In 4 weeks, the total symptom scores were both remarkably improved in two groups （P〈0.05）. In the treatment group, the number of achieved clinical control, excellence and better were 20, 17 and 2 respectively, and the total efficacy was 97.5%. In the control group, there were 18 achieved clinical controls, 16 excellence and 4 better, and the total efficacy was 95.0%. There were no significantly difference between two groups （P〉0.05）. FEV1, PEF and FVC were both made a obvious progress in two groups compared with pre-treatment （P〈0.05）, and without significant difference （P〉0.05）. Conclusion：The Xiaoer Zhike granule could obviously improve the clinical symptoms, signs and lung functions in children with cough variant asthma.
出处
《中医临床研究》
2015年第4期25-27,共3页
Clinical Journal Of Chinese Medicine
基金
2013年深圳市科技计划项目(编号201302127)
